Evidence map›Paper›PMID 40962353›Full record

ArticleBMJ open2025

Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol.

Amanda R Purcell, Natassia Rodrigo, Matilda S G Longfield, Sarah J Glastras

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06180616 (Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06180616 phase2not yet recruitingstarted 2026, after this paper: background citation

Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity: A Placebo-Matched Randomised Controlled Trial

Ran2026Enrolled40Registered outcomes27Posted comparisons0ConditionsOverweight and Obesity, Type 1 Diabetes MellitusArmsTirzepatide
Open the trial in the graph
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Metabolic dysfunction and the use of adjunct medications in type 1 diabetes.Current opinion in endocrinology, diabetes, and obesity · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Amanda R PurcellKolling Institute of Medical Research, St Leonards, New South Wales, Australia.ORCID http://orcid.org/0009-0003-5728-6054
Natassia RodrigoKolling Institute of Medical Research, St Leonards, New South Wales, Australia.
Matilda S G LongfieldKolling Institute of Medical Research, St Leonards, New South Wales, Australia.ORCID http://orcid.org/0000-0002-3795-2254
Sarah J GlastrasKolling Institute of Medical Research, St Leonards, New South Wales, Australia sarah.glastras@sydney.edu.au.ORCID http://orcid.org/0000-0002-9317-1348

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe increasing prevalence of overweight and obesity among individuals with type 1 diabetes (T1D) complicates glycaemic management and escalates insulin resistance, necessitating innovative therapeutic strategies. Tirzepatide, a dual agonist for glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, shows promise in managing weight and glycaemic control in type 2 diabetes but is unexplored in the context of T1D. This double-blind, placebo-controlled randomised trial will evaluate the efficacy of tirzepatide in adults with T1D and overweight/obesity over 32 weeks. METHODS AND ANALYSIS: 60 participants (aged 18-70 years) with a body mass index ≥27 kg/m ETHICS AND DISSEMINATION: Ethical approval has been obtained from the Northern Sydney Local Health District's Human Research Ethics Committee (approval ID #2024/ETH00180). TRIAL REGISTRATION NUMBER: NCT06180616.

Indexed as

Diabetes Mellitus, Type 1Hypoglycemic AgentsObesityOverweightTirzepatideAdolescentAdultAgedBlood GlucoseDouble-Blind MethodFemaleGlycated HemoglobinHumansMaleMiddle AgedRandomized Controlled Trials as TopicBlood GlucoseGlycated HemoglobinHypoglycemic AgentsTirzepatideDiabetes & endocrinologyGeneral diabetesObesityOther metabolic, e.g. iron, porphyriaOverweight

Identifiers

PMID40962353
PMCPMC12443176

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.